1. Crow, M.K., Advances in understanding the role of type I interferons in systemic lupus erythematosus, Curr. Opin. Rheumatol., 2014, vol. 26, no. 5, pp. 467–474.
2. Deryabin, P.G., Isaeva, E.I., Mal’dov, D.G., Il’ichev, A.V, Pichugina, L.V., and L’vov, D.K., The effect of Stimforte on the genotype of the hepatitis C virus strain resistant to interferon, Vopr. Virusol., 2009, no. 2, pp. 17–20.
3. Donnelly, R.P. and Kotenko, S.V., Interferon-lambda: a new addition to an old family, J. Interferon Cytok. Res., 2010, vol. 8, pp. 555–564.
4. Festi, D.I., Sandri, L., Mazzella, G., Roda, E., Sacco, T., Staniscia, T., Capodicasa, S., Vestito, A., and Colecchia, A., Safety of interferon beta treatment for chronic HCV hepatitis, World J. Gastroenterol., 2004, vol. 10, no. 1, pp. 12–16.
5. Gattoni, A., Parlato, A., Vangieri, B., Bresciani, M., and Derna, R., Interferon-gamma: biologic functions and HCV therapy (type I/II) (2 of 2 parts), Clin. Ther., 2006, vol. 157, no. 5, pp. 457–468.